DelveInsight’s “Psoriatic Arthritis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Psoriatic Arthritis pipeline landscapes. It comprises Psoriatic Arthritis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Psoriatic Arthritis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Psoriatic Arthritis pipeline products.
Some of the key takeaways of the Psoriatic Arthritis Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as AbbVie, Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Pfizer, etc., are developing therapies for the treatment of Psoriatic Arthritis.
-
Emerging therapies such as Skyrizi and Rinvoq, Ilumya, Deucravacitinib, Bimekizumab, Brepocitinib, are expected to have a significant impact on the Psoriatic Arthritis market in the coming years.
Get an overview of pipeline landscape @ Psoriatic Arthritis Clinical Trials Analysis
Psoriatic Arthritis Overview
Psoriatic Arthritis is a sort of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but joint problems can sometimes begin before skin patches appear.
Psoriatic Arthritis Emerging Drugs
-
Skyrizi and Rinvoq by AbbVie
-
Ilumya by Sun Pharma
-
Deucravacitinib by Bristol-Myers Squibb
-
Bimekizumab by UCB Biopharma
-
Brepocitinib by Pfizer
-
And others.
Scope of Psoriatic Arthritis Pipeline Drug Insight
-
Coverage: Global
-
Major Players: AbbVie, Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Pfizer, and others.
-
Pipeline Therapies: Skyrizi and Rinvoq, Ilumya, Deucravacitinib, Bimekizumab, Brepocitinib, and others.
Table of Contents
|
1 |
Psoriatic Arthritis Report Introduction |
|
2 |
Psoriatic Arthritis Executive Summary |
|
3 |
Psoriatic Arthritis Overview |
|
4 |
Psoriatic Arthritis- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Psoriatic Arthritis Pipeline Therapeutics |
|
6 |
Psoriatic Arthritis Late Stage Products (Phase II/III) |
|
7 |
Psoriatic Arthritis Mid Stage Products (Phase II) |
|
8 |
Psoriatic Arthritis Early Stage Products (Phase I) |
|
9 |
Psoriatic Arthritis Preclinical Stage Products |
|
10 |
Psoriatic Arthritis Therapeutic Assessment |
|
11 |
Psoriatic Arthritis Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Psoriatic Arthritis Key Companies |
|
14 |
Psoriatic Arthritis Key Products |
|
15 |
Psoriatic Arthritis Unmet Needs |
|
16 |
Psoriatic Arthritis Market Drivers and Barriers |
|
17 |
Psoriatic Arthritis Future Perspectives and Conclusion |
|
18 |
Psoriatic Arthritis Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Related Reports:
DelveInsight’s Psoriatic Arthritis – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Psoriatic Arthritis Epidemiology
DelveInsight’s Psoriatic Arthritis – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Psoriatic Arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/